Wyeth Korea to launch pneumococcal conjugated vaccine Prevenar

Wyeth Korea announced on November 12 that Prevenar received marketing authorization from the Korea Food and Drug Administration.

The vaccine is the first and only pneumococcal conjugated vaccine indicated for infants and young children younger than two years (an age group exposed to a higher incidence of invasive pneumococcal disease and otitis media) to help prevent invasive pneumococcal d...